What do global guidelines say about obesity drugs for children under 10?
Global guidance warns against obesity drugs for children under 10, while the drug evidence mostly comes from adolescents.
Covers: Recommendations from major guideline bodies (such as the WHO, AAP, EASO and NICE) on pharmacological treatment of obesity in children under 10, including when drugs like metformin or GLP-1 receptor agonists are considered and what age limits apply. It does not cover obesity drugs for adolescents or adults, nor detailed dosing or off-label prescribing advice.
Also answers: Are obesity drugs recommended for children under 10? · Guidelines for weight loss medication in young children · What age can children start obesity drugs? · Pediatric obesity medication guidelines worldwide
- One page for this question6 other ways of asking lead here
- 5 independent sourcesEvery claim links to what supports it
- 2 connected pages2 changed this week
- Clean discussionScreened before anything appears
Before you read, make a guess
Fill in the blank: ?% of US children and adolescents affected by pediatric obesity
Drag the slider to fill in the blank
The short answer
Interpretation AI-prepared starting mapThe most recent global guidance in this material is a 2026 World Health Organization position, reported by BBC News, warning against using obesity drugs such as weight-loss injections in children under 10 and saying care should focus on healthy eating and exercise instead. The evidence on drug treatment itself comes mainly from adolescents: a 2026 systematic review and network meta-analysis found that combining lifestyle treatment with obesity medications produced the greatest short-term (typically 6 to 12 months) weight reduction in adolescents with obesity, and that intensive lifestyle treatment alone also produced substantial BMI reductions (mean difference -3.85, 95% CI -4.91 to -2.80, and BMI z score -0.89, 95% CI -1.17 to -0.61, versus control). A 2026 review of GLP-1 and dual GIP/GLP-1 therapies reports clinically meaningful BMI reduction with liraglutide and semaglutide in pediatric trials, with the largest mean effect for semaglutide in adolescents, and notes that no randomized trial has evaluated tirzepatide in pediatric obesity without diabetes.123
- Evidence 11
- Interpretation 7
Did this answer your question?
Be the first to voteIn brief
The latest global guidance in this material, from the WHO in 2026, warns against obesity drugs for children under 10 and points to healthy eating and exercise instead.1
Evidence-backedThe drug evidence cited is mostly from adolescents: combining lifestyle treatment with medication gave the greatest short-term (6 to 12 months) weight reduction, and intensive lifestyle treatment alone also produced substantial BMI reductions.2
Evidence-backedLiraglutide and semaglutide show clinically meaningful BMI reduction in pediatric trials, with the largest mean effect for semaglutide in adolescents; tirzepatide has not been tested in a randomized pediatric trial without diabetes.3
Evidence-backedLong-term effects of these drugs on growth, puberty, bone health, body composition, and weight maintenance remain uncertain.3
Evidence-backedThe material does not include specific NICE or EASO recommendations for under-10s, so the picture of global guidance is incomplete.1
Interpretation
At a glance
The picture in numbers
Live · updated just now
10 years
6 months
17%
17 in every 100
The evidence behind it
5 sources- Reviews of many studies1
- Other studies and data3
- Background1
When it was published
Newest from 2026
| Source | Kind | Year |
|---|---|---|
| New global guidelines warn against obesity drugs for children under 10 | Background | 2026 |
| Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis. | Reviews of many studies | 2026 |
| GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. | Other studies and data | 2026 |
| Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion | Other studies and data | 2008 |
| Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline | Other studies and data | 2017 |
The community around it
No one has added to this page yet. Firsthand experience, a newer study or a different reading of the numbers would show up here, credited to you.
What it means for you
Which fits you?
Pick the situation closest to yours. Each answer says what it rests on.
If you are a parent or carer of a child under 10 with obesity
the latest global guidance in this material points to healthy eating and exercise rather than weight-loss medicines, so that is the starting point to discuss with a clinician.1
Evidence-backedIf you are weighing lifestyle treatment on its own
intensive lifestyle treatment was associated with substantial BMI and BMI z score reductions versus control in the meta-analysis, and remained indispensable alongside any medication.2
Evidence-backedIf you are considering a GLP-1 receptor agonist for a child
the pediatric trial evidence for liraglutide and semaglutide comes largely from adolescents, and long-term effects on growth, puberty, bone health, and weight maintenance are still uncertain.3
Evidence-backedIf you are looking for guidance specific to under-10s from NICE or EASO
this material does not include it, so that question remains open here.1
InterpretationThe full story · 4 chapters
01
What the latest global guidance says
AI summary:WHO's 2026 position warns against obesity drugs for under-10s and favors healthy eating and exercise, while the cited drug evidence is mostly in adolescents.
Evidence-backed: The World Health Organization's 2026 position, as reported by BBC News, warns against obesity drugs for children under 10 and says care should focus on healthy eating and exercise rather than medicines such as weight-loss injections.1
Interpretation: Read together, the material points to a split between what is recommended for young children and what the drug evidence actually covers: the guidance is aimed at under-10s, while the trials and meta-analyses cited are predominantly in adolescents. That gap is the central tension on this page.12
02
What the drug evidence shows, and in whom
AI summary:Combining lifestyle treatment with medication gave the greatest short-term weight reduction in adolescents, and lifestyle treatment alone also helped.
Evidence-backed: A 2026 systematic review and network meta-analysis found that all pharmacological treatments were more effective when paired with lifestyle treatment, producing significantly greater BMI and BMI z score reductions than the same medications alone. Intensive lifestyle treatment as monotherapy was associated with substantial decreases in BMI (mean difference -3.85; 95% CI, -4.91 to -2.80) and BMI z score (mean difference -0.89; 95% CI, -1.17 to -0.61) versus control. The authors concluded that combining lifestyle treatment with obesity medications gave the greatest short-term (typically 6 to 12 months) weight reduction in adolescents with obesity, and that lifestyle treatment remained indispensable.2
Evidence-backed: A 2026 review of GLP-1 and dual GIP/GLP-1 receptor agonists describes how these drugs reduce appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion. It reports clinically meaningful BMI reduction with liraglutide and semaglutide in randomized pediatric trials, with the largest mean effect for semaglutide in adolescents, and notes that tirzepatide has shown greater weight-loss efficacy than selective GLP-1 agonism in adults but has not been evaluated in a randomized trial in pediatric obesity without diabetes. The review argues these therapies should be integrated with nutritional, behavioral, psychological, and family-based care.3
Evidence-backed: The Endocrine Society's 2017 guideline frames pediatric obesity as an international health concern affecting about 17% of US children and adolescents, with genetic susceptibility shaped by the environment from before birth through childhood and adolescence, and notes that endocrine causes of obesity are rare and usually accompanied by attenuated growth. Its 2008 predecessor recommended defining overweight as BMI at or above the 85th but below the 95th percentile and obesity as BMI at or above the 95th percentile, and advised against routine endocrine studies unless height velocity is attenuated or inappropriate for family background or pubertal stage.45
03
Age limits and where the lines fall
AI summary:The clearest age boundary is the under-10 line, a group largely outside the adolescent populations the drug trials studied.
Interpretation: The clearest age boundary in this material is the under-10 line drawn by the WHO position, which steers this group away from medicines and toward healthy eating and exercise. The drug evidence cited sits mostly in adolescents, so the under-10 group is largely outside the populations the trials studied.12
Interpretation: The material does not state whether the WHO guidance treats all drug classes the same way, or whether it distinguishes metformin from GLP-1 receptor agonists, so the scope of the warning for specific medicines in under-10s is not settled here.1
04
What readers are still asking
AI summary:Unanswered questions include how the under-10 group is defined, whether the warning covers all drug classes, and what NICE or EASO say.
Interpretation: The material leaves several practical questions unanswered: how the WHO recommendation defines the under-10 group, whether it applies equally to metformin and to GLP-1 receptor agonists, and what NICE or EASO say specifically about this age band. It also does not resolve how clinicians should weigh the adolescent trial evidence when considering a child under 10, or what long-term monitoring for growth, puberty, and bone health would look like in that group.13
Your turn
Have your say
See where others stand. Join free to add your perspective. One answer per account.
How do you feel about this?
No votes yetQuick questions from connected pages
Before you go
What to remember
Try to recall each hidden figure before you reveal it. Remembering, not rereading, is what makes it stick.
The latest global guidance in this material, from the WHO in 2026, warns against obesity drugs for children under and points to healthy eating and exercise instead.
The material does not include specific NICE or EASO recommendations for under-s, so the picture of global guidance is incomplete.
The drug evidence cited is mostly from adolescents: combining lifestyle treatment with medication gave the greatest short-term (6 to 12 months) weight reduction, and intensive lifestyle treatment alone also produced substantial BMI reductions.
Your reading
0 of 4 chaptersThis answer keeps changing
When new evidence or a better source comes in, this page is updated (it's on version 2, last changed 59 minutes ago). Follow it to be told when that happens.
Up nextWhat are the WHO guidelines on obesity drugs for children under 10?What are the current World Health Organization guidelines on the use of obesity drugs for children under 10 years old?Ask this Sylo
Still wondering about something?
Answers come only from this page's reviewed material, with citations, and say plainly when the page doesn't cover it yet.
Behind this page
Who's adding to it, where it comes from, how it changed and what would make it better. Always open to everyone.
Discussion
Sources
Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.
- 1New global guidelines warn against obesity drugs for children under 10BBC NewsPublished Oct 7, 2026Checked Oct 11, 2026
“Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization”
- 2Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.JAMA pediatrics (Wan et al.)Published Sep 1, 2026Checked Oct 11, 2026
“All pharmacological treatments were more effective when paired with lifestyle treatment, associated with significantly greater BMI and BMI z score reductions than the same medications alone. Based on the primary analysis, HBLT as monotherapy was associated with substantial decreases in BMI (mean difference, -3.85; 95% CI, -4.91 to -2.80) and BMI z score (mean difference, -0.89; 95% CI, -1.17 to -0.61) vs control.Conclusions and relevanceFinding of this systematic review and network meta-analysis suggest that combining lifestyle treatment with obesity management medications was associated with the greatest short-term (typically 6 to 12 months) weight reduction in adolescents with obesity. HBLT remained an indispensable component of any effective weight management, delivering meaningful weight loss and healthier body composition on its own. Combined with lifestyle treatment, pharmacotherapy was a key component, not solely an adjunct, associated with the greatest BMI and BMI z score improvements, and long-term sustainability and safety were monitored.”
- 3GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.International journal of molecular sciences (Myśliwczyk et al.)Published Sep 15, 2026Checked Oct 11, 2026
“We describe how GLP-1 receptor agonists act across central and peripheral tissues to reduce appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion and examine the rationale for dual GIP/GLP-1 receptor agonism. Randomized pediatric trials demonstrate clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents; however, long-term effects on growth, puberty, bone health, body composition, and weight maintenance remain uncertain. Tirzepatide has shown greater weight-loss efficacy than selective GLP-1 receptor agonism in adults, but no randomized trial has evaluated it in pediatric obesity without diabetes. Incretin-based therapies should be integrated with nutritional, behavioral, psychological, and family-based care. Their future value will depend on durable efficacy, developmental safety, equitable access, and identification of patients most likely to benefit.”
- 4Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism (Styne et al.)Published Jan 31, 2017Checked Oct 11, 2026
“Pediatric obesity remains an ongoing serious international health concern affecting ∼17% of US children and adolescents, threatening their adult health and longevity. Pediatric obesity has its basis in genetic susceptibilities influenced by a permissive environment starting in utero and extending through childhood and adolescence. Endocrine etiologies for obesity are rare and usually are accompanied by attenuated growth patterns.”
- 5Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert OpinionThe Journal of Clinical Endocrinology & Metabolism (August et al.)Published Sep 10, 2008Checked Oct 11, 2026
“We recommend defining overweight as body mass index (BMI) in at least the 85th percentile but < the 95th percentile and obesity as BMI in at least the 95th percentile against routine endocrine studies unless the height velocity is attenuated or inappropriate for the family background or stage of puberty; referring patients to a geneticist if there is evidence of a genetic syndrome; evaluating for obesity-associated comorbidities in children with BMI in at least the 85th perce…”
How it changed
Published 1 time since Oct 11, 2026.
- Version 2Oct 11, 2026Live now
AI-prepared Starting Map from live research.
- First published version.
Help improve it
The brief is open about what's uncertain. These are the specific gaps that new material would fill.
“Age limits and where the lines fall” has no evidence or firsthand experience yet
It's a synthesis for now. Evidence or experience would show whether it holds.
“What readers are still asking” has no evidence or firsthand experience yet
It's a synthesis for now. Evidence or experience would show whether it holds.
Open questions
Does the WHO guidance apply to all obesity drugs in under-10s, or does it distinguish between metformin and GLP-1 receptor agonists?
No answers yet
What do NICE and EASO specifically recommend for pharmacological treatment of obesity in children under 10?
No answers yet
How should adolescent trial evidence be weighed when considering a child under 10, given that this age group is largely outside the studied populations?
No answers yet
What long-term monitoring for growth, puberty, bone health, and weight maintenance would be needed if drugs were used in younger children?
No answers yet
Around this topic
Sylos connect: narrower topics report up to broader ones, so what's learned in one place shows up where it matters.